• Redefining
    the posibilities
  • Facilitating
    cell therapy
  • Clients
    choose us
Latest News

Novartis announces an exclusive global licensing and research collaboration with Regenerex
September-6-2013
New research recently published by the hospital suggests organ transplant recipients may not require anti-rejection medication in the future.
April-24-2012
Rob requires no anti-rejection medication more than two years after a combination kidney/stem cell transplant in a clinical trial NSCF funds
February-24-2012
More News
Who are we?
Regenerex, LLC was incorporated in 2002 in Delaware. Regenerex is a biopharmaceutical company based in Louisville Kentucky for production of the company’s proprietary FCRx platform therapy. The hematopoietic stem cell-based immunological tolerance protocol is in the final stages of a
successful FDA Phase II clinical trial in living donor kidney transplant recipients that has resulted in graft survival without the need for lifelong immunosuppression.
Read more
Latest Projects